Literature DB >> 10666674

Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level.

G Lubec1, M Nonaka, K Krapfenbauer, M Gratzer, N Cairns, M Fountoulakis.   

Abstract

Deteriorated migration, axonal pathfinding and wiring of the brain is a main neuropathological feature of Down Syndrome (DS). Information on the underlying mechanisms is still limited, although basic functions of a series of growth factors, cell adhesion molecules, guidance factors and chemoattractants for brain histogenesis have been reported. We used proteomics to detect differences in protein expression between control, DS and Alzheimer's disease brains: In five individual brain regions of 9 individuals of each group we performed two dimensional electrophoresis with MALDI--identification of proteins and determined mRNA levels of DRP-2. Significantly decreased mRNA levels of DRP-2 in four brain regions of patients with DS but not with AD as compared to controls were detected. 2D electrophoresis revealed variable expression of DRP-2 proteins, which showed a high heterogeneity per se. Dysregulation of DRP-2 was found in brains of patients with DS and AD presenting with an inconsistent pattern, which in turn may reflect the inconsistent neuropathological findings in patients with DS and AD. The decrease of mRNA DRP-2 steady state levels in DS along with deteriorated protein expression of this repulsive guidance molecule of the semaphorin/collapsin family, may help to explain deranged migration and histogenesis of DS brain and wiring of AD brain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10666674     DOI: 10.1007/978-3-7091-6380-1_10

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  27 in total

1.  Reduced levels of DEAD-box proteins DBP-RB and p72 in fetal Down syndrome brains.

Authors:  Susanne G Kircher; Seong Hwan Kim; Michael Fountoulakis; Gert Lubec
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

Review 2.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 3.  Redox proteomics in some age-related neurodegenerative disorders or models thereof.

Authors:  D Allan Butterfield; Hafiz Mohmmad Abdul; Shelley Newman; Tanea Reed
Journal:  NeuroRx       Date:  2006-07

4.  Mining functionally relevant gene sets for analyzing physiologically novel clinical expression data.

Authors:  Sevin Turcan; Douglas E Vetter; Jill L Maron; Xintao Wei; Donna K Slonim
Journal:  Pac Symp Biocomput       Date:  2011

Review 5.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

6.  Changes in protein expression in the rat medial vestibular nuclei during vestibular compensation.

Authors:  Janet M Paterson; Duncan Short; Peter W Flatman; Jonathan R Seckl; Alastair Aitken; Mayank B Dutia
Journal:  J Physiol       Date:  2006-07-06       Impact factor: 5.182

7.  Proteomics-determined differences in the concanavalin-A-fractionated proteome of hippocampus and inferior parietal lobule in subjects with Alzheimer's disease and mild cognitive impairment: implications for progression of AD.

Authors:  Joshua B Owen; Fabio Di Domenico; Rukhsana Sultana; Marzia Perluigi; Chiara Cini; William M Pierce; D Allan Butterfield
Journal:  J Proteome Res       Date:  2009-02       Impact factor: 4.466

8.  Neuronal microRNA deregulation in response to Alzheimer's disease amyloid-beta.

Authors:  Nicole Schonrock; Yazi D Ke; David Humphreys; Matthias Staufenbiel; Lars M Ittner; Thomas Preiss; Jürgen Götz
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

Review 9.  Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Acta Neuropathol       Date:  2009-03-14       Impact factor: 17.088

10.  Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study.

Authors:  Ada Fiorini; Rukhsana Sultana; Sarah Förster; Marzia Perluigi; Giovanna Cenini; Chiara Cini; Jian Cai; Jon B Klein; Susan A Farr; Michael L Niehoff; John E Morley; Vijaya B Kumar; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2013-06-15       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.